A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

LESSONS LEARNED. OPB‐111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first‐in‐human phase I study of OPB‐111077 in unselected advanced cancers, treatment‐emergent adverse events, most frequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolcher, Anthony, Flaherty, Keith, Shapiro, Geoffrey I., Berlin, Jordan, Witzig, Thomas, Habermann, Thomas, Bullock, Andrea, Rock, Edwin, Elekes, Agnes, Lin, Chester, Kostic, Dusan, Ohi, Naoto, Rasco, Drew, Papadopoulos, Kyriakos P., Patnaik, Amita, Smith, Lon, Cote, Gregory M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067949/
https://www.ncbi.nlm.nih.gov/pubmed/29511132
http://dx.doi.org/10.1634/theoncologist.2017-0325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067949/
https://www.ncbi.nlm.nih.gov/pubmed/29511132
http://dx.doi.org/10.1634/theoncologist.2017-0325

Ejemplares similares